p.1 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e272

Key Words:  AHA Scientific Statements ◼ acute coronary syndrome ◼ ambulatory ECG monitoring ◼ antiarrhythmic drug therapy ◼ arrhythmogenic cardiomyopathy ◼ athletes ◼ cardiac electrophysiology ◼ cardiac resynchronization therapy ◼ cardiomyopathy ◼ catheter ablation ◼ congenital heart disease ◼ CT imaging ◼ ECG ◼ echocardiography ◼ electrophysiological testing ◼ genetic arrhythmias ◼ guidelines ◼ heart failure ◼ imaging ◼ implantable cardioverterdefibrillator ◼ implantable and external cardioverter devices ◼ medicationinduced arrhythmias ◼ MR imaging ◼ myocardial infarction ◼ premature ventricular beats ◼ resuscitation ◼ sarcoidosis ◼ specific pathology (eg, congenital heart disease, myocarditis, renal failure) ◼ stable coronary artery disease ◼ sudden cardiac arrest ◼ sudden cardiac death ◼ torsades de pointes ◼ ventricular fibrillation ◼ ventricular tachycardia

WRITING COMMITTEE MEMBERS Sana M. Al-Khatib, MD, MHS, FACC, FAHA, FHRS, Chair William G. Stevenson, MD, FACC, FAHA, FHRS, Vice Chair* Michael J. Ackerman, MD, PhD*† William J. Bryant, JD, LLM† David J. Callans, MD, FACC, FHRS*‡ Anne B. Curtis, MD, FACC, FAHA, FHRS*† Barbara J. Deal, MD, FACC, FAHA† Timm Dickfeld, MD, PhD, FHRS*† Michael E. Field, MD, FACC, FAHA, FHRS† Gregg C. Fonarow, MD, FACC, FAHA, FHFSA*§ Anne M. Gillis, MD, FHRS*† Christopher B. Granger, MD, FACC, FAHA*† Stephen C. Hammill, MD, FACC, FHRS‡ Mark A. Hlatky, MD, FACC, FAHA† José A. Joglar, MD, FACC, FAHA, FHRS‖ G. Neal Kay, MD† Daniel D. Matlock, MD, MPH† Robert J. Myerburg, MD, FACC† Richard L. Page, MD, FACC, FAHA, FHRS‡

© 2017 by the American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Rhythm Society.

AHA/ACC/HRS GUIDELINE

2017 AHA/ACC/HRS Guideline for Management

of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Circulation

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. †ACC/AHA Representative. ‡HRS Representative. §ACC/AHA Task Force on Performance Measures Liaison/HFSA Representative. ‖ACC/AHA Task Force on Clinical Practice Guidelines Liaison.

https://www.ahajournals.org/journal/circ

ACC/AHA Task Force Members, see page e354

The American Heart Association requests that this document be cited as follows: Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e272–e391. doi: 10.1161/CIR.0000000000000549. Developed in Collaboration With the Heart Failure Society of America

Downloaded from http://ahajournals.org by on October 7, 2026